Skip to main content
SpringerLink
Log in

Cannabis and Neuropsychiatric Effects

  • Chapter
  • First Online:
Cannabis in Medicine

  • 1512 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

Blunted: The Effects of Cannabis on Cognition and Motivation

  1. Ranganathan M, D’Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology. 2006;188(4):425–44.

    CAS  PubMed  Google Scholar 

  2. Broyd SJ, van Hell HH, Beale C, Yucel M, Solowij N. Acute and chronic effects of cannabinoids on human cognition-a systematic review. Biol Psychiatry. 2016;79(7):557–67.

    CAS  PubMed  Google Scholar 

  3. D’Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29(8):1558–72.

    PubMed  Google Scholar 

  4. Harvey MA, Sellman JD, Porter RJ, Frampton CM. The relationship between non-acute adolescent cannabis use and cognition. Drug Alcohol Rev. 2007;26(3):309–19.

    PubMed  Google Scholar 

  5. Solowij N, Jones KA, Rozman ME, et al. Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. Psychopharmacology. 2011;216(1):131–44.

    CAS  PubMed  Google Scholar 

  6. Lisdahl KM, Price JS. Increased marijuana use and gender predict poorer cognitive functioning in adolescents and emerging adults. J Int Neuropsychol Soc. 2012;18(4):678–88.

    PubMed  PubMed Central  Google Scholar 

  7. Morgan CJ, Gardener C, Schafer G, et al. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med. 2012;42(2):391–400.

    CAS  PubMed  Google Scholar 

  8. Hanson KL, Winward JL, Schweinsburg AD, Medina KL, Brown SA, Tapert SF. Longitudinal study of cognition among adolescent marijuana users over three weeks of abstinence. Addict Behav. 2010;35(11):970–6.

    PubMed  PubMed Central  Google Scholar 

  9. Lyons MJ, Bar JL, Panizzon MS, et al. Neuropsychological consequences of regular marijuana use: a twin study. Psychol Med. 2004;34(7):1239–50.

    CAS  PubMed  Google Scholar 

  10. Tait RJ, Mackinnon A, Christensen H. Cannabis use and cognitive function: 8-year trajectory in a young adult cohort. Addiction. 2011;106(12):2195–203.

    PubMed  Google Scholar 

  11. Winward JL, Hanson KL, Tapert SF, Brown SA. Heavy alcohol use, marijuana use, and concomitant use by adolescents are associated with unique and shared cognitive decrements. J Int Neuropsychol Soc. 2014;20(8):784–95.

    PubMed  PubMed Central  Google Scholar 

  12. Medina KL, Hanson KL, Schweinsburg AD, Cohen-Zion M, Nagel BJ, Tapert SF. Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence. J Int Neuropsychol Soc. 2007;13(5):807–20.

    PubMed  PubMed Central  Google Scholar 

  13. Theunissen EL, Heckman P, de Sousa Fernandes Perna EB, et al. Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans. Psychopharmacology. 2015;232(2):343–53.

    CAS  PubMed  Google Scholar 

  14. Castellano C, Rossi-Arnaud C, Cestari V, Costanzi M. Cannabinoids and memory: animal studies. Curr Drug Targets CNS Neurol Disord. 2003;2(6):389–402.

    CAS  PubMed  Google Scholar 

  15. Collins DR, Pertwee RG, Davies SN. The action of synthetic cannabinoids on the induction of long-term potentiation in the rat hippocampal slice. Eur J Pharmacol. 1994;259(3):R7–8.

    CAS  PubMed  Google Scholar 

  16. Morin JG, Afzali MH, Bourque J, et al. A population-based analysis of the relationship between substance use and adolescent cognitive development. Am J Psychiatry. 2019;176(2):98–106.

    PubMed  Google Scholar 

  17. Auer R, Vittinghoff E, Yaffe K, et al. Association between lifetime marijuana use and cognitive function in middle age: the coronary artery risk development in young adults (CARDIA) study. JAMA Intern Med. 2016;176(3):352–61.

    PubMed  PubMed Central  Google Scholar 

  18. Jouroukhin Y, Zhu X, Shevelkin AV, et al. Adolescent delta(9)-tetrahydrocannabinol exposure and astrocyte-specific genetic vulnerability converge on nuclear factor-kappab-cyclooxygenase-2 signaling to impair memory in adulthood. Biol Psychiatry. 2019;85(11):891–903.

    CAS  PubMed  Google Scholar 

  19. Verrico CD, Gu H, Peterson ML, Sampson AR, Lewis DA. Repeated delta9-tetrahydrocannabinol exposure in adolescent monkeys: persistent effects selective for spatial working memory. Am J Psychiatry. 2014;171(4):416–25.

    PubMed  PubMed Central  Google Scholar 

  20. Rubino T, Parolaro D. The impact of exposure to cannabinoids in adolescence: insights from animal models. Biol Psychiatry. 2016;79(7):578–85.

    CAS  PubMed  Google Scholar 

  21. Sandler RA, Fetterhoff D, Hampson RE, Deadwyler SA, Marmarelis VZ. Cannabinoids disrupt memory encoding by functionally isolating hippocampal ca1 from ca3. PLoS Comput Biol. 2017;13(7):e1005624.

    PubMed  PubMed Central  Google Scholar 

  22. Campolongo P, Trezza V, Cassano T, et al. Perinatal exposure to delta-9-tetrahydrocannabinol causes enduring cognitive deficits associated with alteration of cortical gene expression and neurotransmission in rats. Addict Biol. 2007;12(3–4):485–95.

    CAS  PubMed  Google Scholar 

  23. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML. Prevention of alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci. 2005;25(8):1904–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Calabrese EJ, Rubio-Casillas A. Biphasic effects of thc in memory and cognition. Eur J Clin Investig. 2018;48(5):e12920.

    Google Scholar 

  25. Broers B, Pata Z, Mina A, Wampfler J, de Saussure C, Pautex S. Prescription of a THC/CBD-based medication to patients with dementia: a pilot study in Geneva. Med Cann Cannabinoids. 2019;2:56–9.

    Google Scholar 

  26. Batalla A, Bhattacharyya S, Yucel M, et al. Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS One. 2013;8(2):e55821.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Grant IR, Gonzales CL, Carey LN, Wolfon T. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc. 2003;9:679–89.

    CAS  PubMed  Google Scholar 

  28. Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis. Exp Clin Psychopharmacol. 2012;20(5):420–9.

    PubMed  Google Scholar 

  29. National Academies of Sciences E, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, D.C.: The National Academies Press; 2017.

    Google Scholar 

  30. Hooper SR, Woolley D, De Bellis MD. Intellectual, neurocognitive, and academic achievement in abstinent adolescents with cannabis use disorder. Psychopharmacology. 2014;231(8):1467–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Oomen PP, van Hell HH, Bossong MG. The acute effects of cannabis on human executive function. Behav Pharmacol. 2018;29(7):605–16.

    CAS  PubMed  Google Scholar 

  32. Gruber SA, Sagar KA, Dahlgren MK, Racine M, Lukas SE. Age of onset of marijuana use and executive function. Psychol Addict Behav. 2012;26(3):496–506.

    PubMed  Google Scholar 

  33. Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol. 2009;23(3):266–77.

    CAS  PubMed  Google Scholar 

  34. Thames AD, Arbid N, Sayegh P. Cannabis use and neurocognitive functioning in a non-clinical sample of users. Addict Behav. 2014;39(5):994–9.

    PubMed  PubMed Central  Google Scholar 

  35. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A. 2012;109(40):E2657–64.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Fried P, Watkinson B, James D, Gray R. Current and former marijuana use: preliminary findings of a longitudinal study of effects on iq in young adults. CMAJ. 2002;166(7):887–91.

    PubMed  PubMed Central  Google Scholar 

  37. Jackson NJ, Isen JD, Khoddam R, et al. Impact of adolescent marijuana use on intelligence: results from two longitudinal twin studies. Proc Natl Acad Sci U S A. 2016;113(5):E500–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Barnwell SS, Earleywine M, Wilcox R. Cannabis, motivation, and life satisfaction in an internet sample. Subst Abuse Treat Prev Policy. 2006;1:2.

    PubMed  PubMed Central  Google Scholar 

  39. Lac A, Luk JW. Testing the amotivational syndrome: marijuana use longitudinally predicts lower self-efficacy even after controlling for demographics, personality, and alcohol and cigarette use. Prev Sci. 2018;19(2):117–26.

    PubMed  PubMed Central  Google Scholar 

  40. Macher RB, Earleywine M. Enhancing neuropsychological performance in chronic cannabis users: the role of motivation. J Clin Exp Neuropsychol. 2012;34(4):405–15.

    PubMed  Google Scholar 

  41. Smith DE. Acute and chronic toxicity of marijuana. J Psychoactive Drugs. 1968;2(1):37–48.

    Google Scholar 

  42. Volkow ND, Swanson JM, Evins AE, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiat. 2016;73(3):292–7.

    Google Scholar 

  43. Lawn W, Freeman TP, Pope RA, et al. Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses. Psychopharmacology. 2016;233(19–20):3537–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Paule MG, Allen RR, Bailey JR, et al. Chronic marijuana smoke exposure in the rhesus monkey. Ii: effects on progressive ratio and conditioned position responding. J Pharmacol Exp Ther. 1992;260(1):210–22.

    CAS  PubMed  Google Scholar 

  45. Rubino T, Realini N, Braida D, et al. The depressive phenotype induced in adult female rats by adolescent exposure to THC is associated with cognitive impairment and altered neuroplasticity in the prefrontal cortex. Neurotox Res. 2009;15(4):291–302.

    CAS  PubMed  Google Scholar 

  46. Rubino T, Realini N, Braida D, et al. Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. Hippocampus. 2009;19(8):763–72.

    CAS  PubMed  Google Scholar 

  47. Gleason KA, Birnbaum SG, Shukla A, Ghose S. Susceptibility of the adolescent brain to cannabinoids: long-term hippocampal effects and relevance to schizophrenia. Transl Psychiatry. 2012;2:e199.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Landfield PW. Hippocampal neurobiological mechanisms of age-related memory dysfunction. Neurobiol Aging. 1988;9(5–6):571–9.

    CAS  PubMed  Google Scholar 

  49. Brandon NJ, Sawa A. Linking neurodevelopmental and synaptic theories of mental illness through disc1. Nat Rev. 2011;12(12):707–22.

    CAS  Google Scholar 

  50. Hebert-Chatelain E, Desprez T, Serrat R, et al. A cannabinoid link between mitochondria and memory. Nature. 2016;539(7630):555–9.

    CAS  PubMed  Google Scholar 

  51. Bossong MG, Mehta MA, van Berckel BN, Howes OD, Kahn RS, Stokes PR. Further human evidence for striatal dopamine release induced by administration of 9-tetrahydrocannabinol (THC): selectivity to limbic striatum. Psychopharmacology. 2015;232(15):2723–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Bloomfield MA, Morgan CJ, Egerton A, Kapur S, Curran HV, Howes OD. Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry. 2014;75(6):470–8.

    CAS  PubMed  Google Scholar 

  53. Martz ME, Trucco EM, Cope LM, et al. Association of marijuana use with blunted nucleus accumbens response to reward anticipation. JAMA Psychiat. 2016;73(8):838–44.

    Google Scholar 

  54. Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across europe (eu-gei): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427–36.

    PubMed  Google Scholar 

  55. Garavan H, Bartsch H, Conway K, Decastro A, Goldstein RZ, Heeringa S, et al. Recruiting the ABCD sample: design considerations and procedures. Dev Cogn Neurosci. 2018;32:16–22.

    CAS  PubMed  PubMed Central  Google Scholar 

Cannabis and Psychiatric Conditions

  1. Shrivastava A, Johnston M, Terpstra K, Bureau Y. Cannabis and psychosis: neurobiology. Indian J Psychiatry. 2014 [cited 2014 Feb 13]; 56:8–16. Available from: http://www.indianjpsychiatry.org/text.asp?2014/56/1/8/124708.

  2. Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse health effects of marijuana use. N Engl J Med. 2014;370:2219–27.

    PubMed  PubMed Central  Google Scholar 

  3. Seth A, Sheryl R, William PA. The impact of cannabis policies on youth clinical research and legal update. American Academy of Pediatrics. Denver, Colorado: 2015.

  4. Joseph M, Pierre MD. Risks of increasingly potent Cannabis: the joint effects of potency and frequency. Curr Psychiatr Ther. 2017;16:14–20.

    Google Scholar 

  5. Strougo A, Zuurman L, Roy C, Pinquier JL, van Gerven JMA, Cohen AF, Schoemaker C. Modelling of the concentration—effect relationship of THC on central nervous system parameters and heart rate — insight into its mechanisms of action and a tool for clinical research and development of cannabinoids. J Psychopharmacol. 2008;22:717–26.

    CAS  PubMed  Google Scholar 

  6. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffit TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325:1212. Available from https://doi.org/10.1136/bmj.325.7374.1212.

  7. Cohen M, et al. Cannabis, cannabinoids and schizophrenia: integration of the evidence. Aust N Z J Psychiatry. 2008;42:357–68.

    PubMed  Google Scholar 

  8. Doris C, Gundersen MD. The legalization of marijuana: implications for regulation and practice. J Nurs Regul. 2015;6:3. Available from www.journalofnursingregulation.com

    Google Scholar 

  9. de Shazo RD, et al. Marijuana’s effects on brain structure and function: what do we know and what should we do? A brief review and commentary. Am J Med. 2019;132(3):281–5.

    Google Scholar 

  10. McGrath J, et al. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry. 2010;67(5):440–7.

    PubMed  Google Scholar 

  11. Di Forti M, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry. 2015;2:233–8.

    PubMed  Google Scholar 

  12. Copeland J, et al. Changes in cannabis use among young people: impact on mental health. Curr Opin Psych. 2013;26(4):325–9.

    Google Scholar 

  13. Crippa J, Zuardi AW, Martin-Santos R, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol Clin Exp. 2009; https://doi.org/10.1002/hup.104.

  14. Cheung J, et al. Anxiety and mood disorders and Cannabis use. Am J Drug Alcohol Abuse. 2010;36(2):118–22.

    PubMed  Google Scholar 

  15. Degenhardt L, et al. The Persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction. 2013;108(1):124–33.

    PubMed  Google Scholar 

  16. Bahorik AL et al, Patterns of marijuana use among psychiatry patients with depression and its impact on recovery. J Affect Disord 2017;312: 168–171.

    Google Scholar 

  17. Ho H, Hewitt J, Hopfer C. Temporal relationship between cannabis use and depression among adolescents in the United States. [Poster presentation]. American Psychiatric Association Annual Conference. Institute of Medicine; 2015.

    Google Scholar 

  18. Hayatbakhsh MR, et al. Cannabis and anxiety and depression in young adults: a large prospective study. J Am Acad Child Adolesc Psychiatry. 2007;46(3):408–17.

    PubMed  Google Scholar 

  19. Wang GS, et al. Impact of marijuana legalization in Colorado on adolescent emergency and urgent care visits. J Adolesc Health. 2018;63(2):239–41.

    PubMed  Google Scholar 

  20. Wilkinson ST, et al. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry. 2015;76(9):1174–80.

    PubMed  PubMed Central  Google Scholar 

  21. Bitencourt R, Takahash R. Cannabidiol as a therapeutic alternative for post traumatic stress disorder: from bench research to confirmation in human trials. Front Neurosci. 2018;12:502.

    PubMed  PubMed Central  Google Scholar 

  22. https://militarybenefits.info/va-medical-marijuana.

  23. Rocky Mountain High Intensity Drug Trafficking Area (RMHIDTA) Investigative Support Center. The legalization of Marijuana in Colorado: the impact, vol 2. Denver, Colorado: 2014.

    Google Scholar 

  24. Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the national comorbidity survey. Exp Clin Psychopharmacol. 1994;2(3):244–68.

    Google Scholar 

  25. Matochik JA, Eldreth DA, Cadet JL, Bolla KI. Altered brain tissue composition in heavy Cannabis users. Drug Alcohol Depend. 2005;77(1):23–30.

    CAS  PubMed  Google Scholar 

  26. Gundersen DC. Medical Cannabis—a prescription for trouble? CPHP News. 2010. Retrieved from www.cphp.org/documents/CPHPnews-summer-2010.pdf.

  27. https://www.drugabuse.gov/publications/research-reports/marijuana/marijuana-addictive.

  28. Prescription drug abuse prevention: a colorado community reference 2018. www.corxconsortium.org/heroin-response-work-group/.

  29. Buckner D, et al. Cannabis use and suicidal ideation: test of the utility of the interpersonal-psychological theory of suicide. Psychiatry Res. 2017;253:256–9.

    PubMed  PubMed Central  Google Scholar 

  30. Kimbrel NA, et al. Cannabis use disorder and suicide attempts in Iraq/Afghanistan-era veterans. J Psychiatr Res. 2017;89:1–5.

    PubMed  PubMed Central  Google Scholar 

  31. Silins E, et al. Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiatry. 2014;1(4):286–93.

    PubMed  Google Scholar 

  32. Dugre JR, et al. Persistency of cannabis use predicts violence following acute psychiatric discharge. Front Psychiatry. 2017;8:176.

    PubMed  PubMed Central  Google Scholar 

  33. Moulin V, et al. Cannabis, a significant risk factor for violent Behavior in the early phase of psychosis. Two patterns of interaction of factors increase the risk of violent behavior: cannabis use disorder, lack of insight and treatment adherence, frontiers of psychiatry 2018. Available from https://doi.org/10.3389/fpsyt.2018.00294.

  34. Volkow ND, Baler R. Emergency department visits from edible versus inhalable Cannabis. Ann Intern Med. 2019;170:569–70.

    PubMed  Google Scholar 

  35. Niesink RJ, van Laar MW. Does cannabidiol protect against adverse psychological effects of THC? Front Psych. 2013;4:130.

    Google Scholar 

  36. Demirakca T, Sartorius A, Ende G, et al. Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug Alcohol Depend. 2011;114:242–5.

    CAS  PubMed  Google Scholar 

  37. Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry. 2008;192:306–7.

    PubMed  Google Scholar 

  38. Morgan CJ, Schafer G, Freeman TP, Curran HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study [corrected]. Br J Psychiatry. 2010;197:285–90.

    PubMed  Google Scholar 

  39. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35:764–74.

    CAS  PubMed  Google Scholar 

  40. Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res. 2011;130:216–21.

    PubMed  Google Scholar 

  41. Hallak JE, Dursun SM, Bosi DC, et al. The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35:198–202.

    CAS  Google Scholar 

  42. Zuardi AW, Morais SL, Guimarães FS, Mechoulam R. Anti-psychotic effect of cannabidiol. J Clin Psychiatry. 1995;56:485–6.

    CAS  PubMed  Google Scholar 

  43. Leweke FM, Koethe D, Gerth CW, et al. Cannabidiol as an antipsychotic. A double-blind, controlled clinical trial on cannabidiol vs. amisulpride in acute schizophrenia. Eur Psychiatry. 2007;22:S14.02.

    Google Scholar 

  44. Gomes FV, Del Bel EA, Guimarães FS. Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;46:43–7.

    CAS  Google Scholar 

  45. Zuardi AW, Cosme RA, Graeff FG, Guimarães FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol. 1993;7(1 Suppl):82–8.

    CAS  PubMed  Google Scholar 

  46. Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011;25:121–30.

    CAS  PubMed  Google Scholar 

  47. Fusar-Poli P, Crippa JA, Bhattacharyya S, et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. 2009;66:95–105.

    CAS  PubMed  Google Scholar 

  48. Gazarini L, Stern CA, Piornedo RR, Takahashi RN, Bertoglio LJ. PTSD-like memory generated through enhanced noradrenergic activity is mitigated by a dual step pharmacological intervention targeting its reconsolidation. Int J Neuropsychopharmacol. 2014;18

    Google Scholar 

  49. Das RK, Kamboj SK, Ramadas M, et al. Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacol (Berl). 2013;226:781–92.

    CAS  Google Scholar 

  50. Schatman ME. Medical marijuana: the state of the science, medscape psychiatry. 2015.

    Google Scholar 

  51. Morgan CJ, Das RK, Joye A, Curran HV, Kamboj SK. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav. 2013;38:2433–6.

    PubMed  Google Scholar 

  52. file:///C:/Users/dorisg/Documents/EPIDIOLEX_Full_Prescribing_Information.pdf.

    Google Scholar 

  53. American Psychiatric Association Resource Document on opposition to cannabis as medicine, approved by the Joint Reference Committee, October 2018.

    Google Scholar 

Cannabis Use and Psychosis, Mood, and Anxiety Disorders

  1. Murray RM, Englund A, Abi-Dargham A, Lewis DA, Di Forti M, Davies C, et al. Cannabis-associated psychosis: neural substrate and clinical impact. Neuropharmacology. 2017;124:89–104.

    CAS  PubMed  Google Scholar 

  2. ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in Cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psychiatry. 2016;79(7):613–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Smart R, Caulkins JP, Kilmer B, Davenport S, Midgette G. Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Addiction. 2017;112(12):2167–77.

    PubMed  PubMed Central  Google Scholar 

  4. Leafly Staff. A Guide to Cannabis Concentrates: Part 4, Cannabis Concentrates for Experts [Internet]. [updated 2019 June 14; cited 2019 Sept 6]. Available from: https://www.leafly.com/news/strains-products/marijuana-extracts-dabs-for-experts.

  5. Bennett P. THCA and CBD Crystalline: Cannabinoids at Their Purest 2018 [Internet]. [updated 2018 Mar 22; cited 2019 Sept 6]. Available from: https://www.leafly.com/news/strains-products/what-are-thca-cbda-crystalline-cannabinoids.

  6. Sideli L, Quigley H, La Cascia C, Murray RM. Cannabis use and the risk of psychosis and affective disorders. J Dual Diagn. 2019;16:22–42.

    PubMed  Google Scholar 

  7. Murrie B, Lappin J, Large M, Sara G. Transition of substance-induced, brief, and atypical psychoses to schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2019;16:sbz102.

    Google Scholar 

  8. Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, et al. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiat. 2015;72(12):1235–42.

    Google Scholar 

  9. Johnston LD, Miech RA, O'Malley PM, Bachman JG, Schulenberg JE, Patrick ME. Monitoring the future National Survey Results on drug use, 1975–2018. Ann Arbor: Institute for Social Research, University of Michigan; 2019.

    Google Scholar 

  10. Kann L, McManus T, Harris WA, Shanklin SL, Flint KH, Queen B, et al. Youth risk behavior surveillance - United States, 2017. MMWR Surveill Summ. 2018;67(8):1–114.

    PubMed  PubMed Central  Google Scholar 

  11. Wilson J, Freeman TP, Mackie CJ. Effects of increasing cannabis potency on adolescent health. Lancet Child Adolesc Health. 2019;3(2):121–8.

    PubMed  Google Scholar 

  12. van Ours JC, Williams J, Fergusson D, Horwood LJ. Cannabis use and suicidal ideation. J Health Econ. 2013;32(3):524–37.

    PubMed  Google Scholar 

  13. Gage SH, Hickman M, Heron J, Munafo MR, Lewis G, Macleod J, et al. Associations of cannabis and cigarette use with depression and anxiety at age 18: findings from the Avon longitudinal study of parents and children. PLoS One. 2015;10(4):e0122896.

    PubMed  PubMed Central  Google Scholar 

  14. Agrawal A, Nelson EC, Bucholz KK, Tillman R, Grucza RA, Statham DJ, et al. Major depressive disorder, suicidal thoughts and behaviours, and cannabis involvement in discordant twins: a retrospective cohort study. Lancet Psychiatry. 2017;4(9):706–14.

    PubMed  PubMed Central  Google Scholar 

  15. Walsh Z, Callaway R, Belle-Isle L, Capler R, Kay R, Lucas P, et al. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Policy. 2013;24(6):511–6.

    PubMed  Google Scholar 

  16. Turna J, Simpson W, Patterson B, Lucas P, Van Ameringen M. Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users. J Psychiatr Res. 2019;111:134–9.

    PubMed  Google Scholar 

  17. Smit F, Bolier L, Cuijpers P. Cannabis use and the risk of later schizophrenia: a review. Addiction. 2004;99(4):425–30.

    PubMed  Google Scholar 

  18. Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr Bull. 2005;31(3):608–12.

    PubMed  Google Scholar 

  19. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet. 1987;330(8574):1483–6.

    Google Scholar 

  20. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002;325(7374):1199.

    PubMed  PubMed Central  Google Scholar 

  21. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ. 2005;330(7481):11.

    PubMed  PubMed Central  Google Scholar 

  22. Valmaggia LR, Day FL, Jones C, Bissoli S, Pugh C, Hall D, et al. Cannabis use and transition to psychosis in people at ultra-high risk. Psychol Med. 2014;44(12):2503–12.

    CAS  PubMed  Google Scholar 

  23. Jacobus J, Tapert SF. Effects of cannabis on the adolescent brain. Curr Pharm Des. 2014;20(13):2186–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. van Nierop M, Janssens M, Genetic Risk OoPI, Bruggeman R, Cahn W, de Haan L, et al. Evidence that transition from health to psychotic disorder can be traced to semi-ubiquitous environmental effects operating against background genetic risk. PLoS One. 2013;8(11):e76690.

    Google Scholar 

  25. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319–28.

    PubMed  Google Scholar 

  26. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325(7374):1212–3.

    PubMed  PubMed Central  Google Scholar 

  27. Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol Med. 2003;33(1):15–21.

    CAS  PubMed  Google Scholar 

  28. Tien AY, Anthony JC. Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences. J Nerv Ment Dis. 1990;178(8):473–80.

    CAS  PubMed  Google Scholar 

  29. Wiles NJ, Zammit S, Bebbington P, Singleton N, Meltzer H, Lewis G. Self-reported psychotic symptoms in the general population: results from the longitudinal study of the British National Psychiatric Morbidity Survey. Br J Psychiatry. 2006;188:519–26.

    PubMed  Google Scholar 

  30. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 2002;156(4):319–27.

    PubMed  Google Scholar 

  31. Schubart CD, van Gastel WA, Breetvelt EJ, Beetz SL, Ophoff RA, Sommer IE, et al. Cannabis use at a young age is associated with psychotic experiences. Psychol Med. 2011;41(6):1301–10.

    CAS  PubMed  Google Scholar 

  32. Mosher CJ, Akins S. Medical and recreational marijuana legalization process. In: In the weeds: demonization, legalization, and the evolution of US marijuana policy. Philadelphia: Temple University Press; 2019.

    Google Scholar 

  33. Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427–36.

    PubMed  Google Scholar 

  34. Barbeito S, Vega P, Ruiz de Azua S, Saenz M, Martinez-Cengotitabengoa M, Gonzalez-Ortega I, et al. Cannabis use and involuntary admission may mediate long-term adherence in first-episode psychosis patients: a prospective longitudinal study. BMC Psychiatry. 2013;13:326.

    PubMed  PubMed Central  Google Scholar 

  35. Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry. 2006;189:229–34.

    CAS  PubMed  Google Scholar 

  36. Dervaux A, Laqueille X, Bourdel MC, Leborgne MH, Olie JP, Loo H, et al. Cannabis and schizophrenia: demographic and clinical correlates. Encéphale. 2003;29(1):11–7.

    CAS  PubMed  Google Scholar 

  37. Grech A, Van Os J, Jones PB, Lewis SW, Murray RM. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry. 2005;20(4):349–53.

    PubMed  Google Scholar 

  38. Caspari D. Cannabis and schizophrenia: results of a follow-up study. Eur Arch Psychiatry Clin Neurosci. 1999;249(1):45–9.

    CAS  PubMed  Google Scholar 

  39. Hjorthoj C, Ostergaard ML, Benros ME, Toftdahl NG, Erlangsen A, Andersen JT, et al. Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide, prospective, register-based study. Lancet Psychiatry. 2015;2(9):801–8.

    PubMed  Google Scholar 

  40. Schoeler T, Petros N, Di Forti M, Klamerus E, Foglia E, Ajnakina O, et al. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. Lancet Psychiatry. 2016;3(10):947–53.

    PubMed  Google Scholar 

  41. Schoeler T, Petros N, Di Forti M, Klamerus E, Foglia E, Murray R, et al. Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis. Lancet Psychiatry. 2017;4(8):627–33.

    PubMed  PubMed Central  Google Scholar 

  42. Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry. 2008;192(4):306–7.

    PubMed  Google Scholar 

  43. Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res. 2011;130(1–3):216–21.

    PubMed  Google Scholar 

  44. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:e94.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2018;175(3):225–31.

    PubMed  Google Scholar 

  46. Myles N, Newall H, Nielssen O, Large M. The association between cannabis use and earlier age at onset of schizophrenia and other psychoses: meta-analysis of possible confounding factors. Curr Pharm Des. 2012;18(32):5055–69.

    CAS  PubMed  Google Scholar 

  47. Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 2014;40(6):1509–17.

    PubMed  Google Scholar 

  48. Cougle JR, Hakes JK, Macatee RJ, Chavarria J, Zvolensky MJ. Quality of life and risk of psychiatric disorders among regular users of alcohol, nicotine, and cannabis: an analysis of the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). J Psychiatr Res. 2015;66–67:135–41.

    PubMed  Google Scholar 

  49. Carra G, Bartoli F, Crocamo C. Trends of major depressive episode among people with cannabis use: findings from the National Survey on drug use and health 2006-2015. Subst Abus. 2019;40(2):178–84.

    PubMed  Google Scholar 

  50. Hayatbakhsh MR, Najman JM, Jamrozik K, Mamun AA, Alati R, Bor W. Cannabis and anxiety and depression in young adults: a large prospective study. J Am Acad Child Adolesc Psychiatry. 2007;46(3):408–17.

    PubMed  Google Scholar 

  51. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. BMJ. 2002;325(7374):1195–8.

    PubMed  PubMed Central  Google Scholar 

  52. Degenhardt L, Hall W, Lynskey M. Exploring the association between cannabis use and depression. Addiction. 2003;98(11):1493–504.

    PubMed  Google Scholar 

  53. Kedzior KK, Laeber LT. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population–a meta-analysis of 31 studies. BMC Psychiatry. 2014;14:136.

    PubMed  PubMed Central  Google Scholar 

  54. Gobbi G, Atkin T, Zytynski T, Wang S, Askari S, Boruff J, et al. Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: a systematic review and meta-analysis. JAMA Psychiat. 2019;76(4):426–34.

    Google Scholar 

  55. Feingold D, Weiser M, Rehm J, Lev-Ran S. The association between cannabis use and anxiety disorders: results from a population-based representative sample. Eur Neuropsychopharmacol. 2016;26(3):493–505.

    CAS  PubMed  Google Scholar 

  56. Guttmannova K, Kosterman R, White HR, Bailey JA, Lee JO, Epstein M, et al. The association between regular marijuana use and adult mental health outcomes. Drug Alcohol Depend. 2017;179:109–16.

    PubMed  PubMed Central  Google Scholar 

  57. Schoeler T, Theobald D, Pingault JB, Farrington DP, Coid JW, Bhattacharyya S. Developmental sensitivity to cannabis use patterns and risk for major depressive disorder in mid-life: findings from 40 years of follow-up. Psychol Med. 2018;48(13):2169–76.

    PubMed  Google Scholar 

  58. Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med. 2014;44(4):797–810.

    CAS  PubMed  Google Scholar 

  59. Rasic D, Weerasinghe S, Asbridge M, Langille DB. Longitudinal associations of cannabis and illicit drug use with depression, suicidal ideation and suicidal attempts among Nova Scotia high school students. Drug Alcohol Depend. 2013;129(1–2):49–53.

    PubMed  Google Scholar 

  60. Degenhardt L, Coffey C, Romaniuk H, Swift W, Carlin JB, Hall WD, et al. The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction. 2013;108(1):124–33.

    PubMed  Google Scholar 

  61. van Laar M, van Dorsselaer S, Monshouwer K, de Graaf R. Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population? Addiction. 2007;102(8):1251–60.

    PubMed  Google Scholar 

  62. Brook JS, Zhang C, Brook DW. Developmental trajectories of marijuana use from adolescence to adulthood: personal predictors. Arch Pediatr Adolesc Med. 2011;165(1):55–60.

    PubMed  PubMed Central  Google Scholar 

  63. Bahorik AL, Leibowitz A, Sterling SA, Travis A, Weisner C, Satre DD. Patterns of marijuana use among psychiatry patients with depression and its impact on recovery. J Affect Disord. 2017;213:168–71.

    PubMed  PubMed Central  Google Scholar 

  64. Moitra E, Anderson BJ, Stein MD. Reductions in Cannabis use are associated with mood improvement in female emerging adults. Depress Anxiety. 2016;33(4):332–8.

    PubMed  Google Scholar 

  65. van Rossum I, Boomsma M, Tenback D, Reed C, van Os J, Board EA. Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis. J Nerv Ment Dis. 2009;197(1):35–40.

    PubMed  Google Scholar 

  66. Kim SW, Dodd S, Berk L, Kulkarni J, de Castella A, Fitzgerald PB, et al. Impact of cannabis use on long-term remission in bipolar I and schizoaffective disorder. Psychiatry Investig. 2015;12(3):349–55.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Zorrilla I, Aguado J, Haro JM, Barbeito S, Lopez Zurbano S, Ortiz A, et al. Cannabis and bipolar disorder: does quitting cannabis use during manic/mixed episode improve clinical/functional outcomes? Acta Psychiatr Scand. 2015;131(2):100–10.

    CAS  PubMed  Google Scholar 

  68. Ostergaard MLD, Nordentoft M, Hjorthoj C. Associations between substance use disorders and suicide or suicide attempts in people with mental illness: a Danish nation-wide, prospective, register-based study of patients diagnosed with schizophrenia, bipolar disorder, unipolar depression or personality disorder. Addiction. 2017;112(7):1250–9.

    PubMed  Google Scholar 

Marijuana and Suicide: Case-control Studies, Population Data and Potential Neurochemical Mechanisms

  1. Nock MK, Banaji MR. Prediction of suicide ideation and attempts among adolescents using a brief performance-based test. J Consult Clin Psychol. 2007;75(5):707–15.

    PubMed  PubMed Central  Google Scholar 

  2. Silverman MM, Berman AL, Sanddal ND, O’carroll PW, Joiner TE. Rebuilding the tower of Babel: a revised nomenclature for the study of suicide and suicidal behaviors. Part 2: suicide-related ideations, communications, and behaviors. Suicide Life Threat Behav. 2007;37(3):264–77.

    PubMed  Google Scholar 

  3. Arria AM, O’Grady KE, Caldeira KM, Vincent KB, Wilcox HC, Wish ED. Suicide ideation among college students: a multivariate analysis. Arch Suicide Res. 2009;13(3):230–46.

    PubMed  PubMed Central  Google Scholar 

  4. McHugh CM, Corderoy A, Ryan CJ, Hickie IB, Large MM. Association between suicidal ideation and suicide: meta-analyses of odds ratios, sensitivity, specificity and positive predictive value. BJPsych Open. 2019;5(2):e1.

    Google Scholar 

  5. Nordström P, Asberg M, Aberg-Wistedt A, Nordin C. Attempted suicide predicts suicide risk in mood disorders. Acta Psychiatr Scand. 1995;92(5):345–50.

    PubMed  Google Scholar 

  6. Hawton K, Casañas I, Comabella C, Haw C, Saunders K. Risk factors for suicide in individuals with depression: a systematic review. J Affect Disord. 2013;147(1–3):17–28.

    PubMed  Google Scholar 

  7. Wong SS, Zhou B, Goebert D, Hishinuma ES. The risk of adolescent suicide across patterns of drug use: a nationally representative study of high school students in the United States from 1999 to 2009. Soc Psychiatry Psychiatr Epidemiol. 2013;48(10):1611–20.

    Google Scholar 

  8. O’Boyle M, Brandon EA. Suicide attempts, substance abuse, and personality. J Subst Abus Treat. 1998;15(4):353–6.

    Google Scholar 

  9. Kokkevi A, Rotsika V, Arapaki A, Richardson C. Adolescents’ self-reported suicide attempts, self-harm thoughts and their correlates across 17 European countries. J Child Psychol Psychiatry. 2012;53(4):381–9.

    CAS  PubMed  Google Scholar 

  10. Conner KR, Britton PC, Sworts LM, Joiner TE. Suicide attempts among individuals with opiate dependence: the critical role of belonging. Addict Behav. 2007;32(7):1395–404.

    PubMed  Google Scholar 

  11. Darke S, Ross J. Suicide among heroin users: rates, risk factors and methods. Addiction. 2002;97(11):1383–94.

    PubMed  Google Scholar 

  12. Mykletun A, Bjerkeset O, Dewey M, Prince M, Overland S, Stewart R. Anxiety, depression, and cause-specific mortality: the HUNT study. Psychosom Med. 2007;69(4):323–31.

    PubMed  Google Scholar 

  13. Zhang J, Li Z. The association between depression and suicide when hopelessness is controlled for. Compr Psychiatry. 2013;54(7):790–6.

    PubMed  PubMed Central  Google Scholar 

  14. Darke S, Ross J, Marel C, Mills KL, Slade T, Burns L, Teesson M. Patterns and correlates of attempted suicide amongst heroin users: 11-year follow-up of the Australian treatment outcome study cohort. Psychiatry Res. 2015;227(2–3):166–70.

    PubMed  Google Scholar 

  15. Marzuk PM, Tardiff K, Lepn AC, Stajic M, Morgan EB, Mann JJ. Prevalence of cocaine use among residents of New York City who committed suicide during a one-year period. Am J Psychiatry. 1992;149(3):371–5.

    CAS  PubMed  Google Scholar 

  16. Fowler RC, Rich CL, Young D. San Diego Suicide Study. II. Substance abuse in young cases. Arch Gen Psychiatry. 1986;43(10):962–5.

    CAS  PubMed  Google Scholar 

  17. Glasheen C, Pemberton MR, Lipari R, Copello EA, Mattson ME. Binge drinking and the risk of suicidal thoughts, plans, and attempts. Addict Behav. 2015;43:42–9.

    PubMed  Google Scholar 

  18. Bagge CL, Borges G. Acute substance use as a warning sign for suicide attempts: a case-crossover examination of the 48 hours prior to a recent suicide attempt. J Clin Psychiatry. 2017;78(6):691–6.

    PubMed  Google Scholar 

  19. Clarke MC, Coughlan H, Harley M, Connor D, Power E, Lynch F, et al. The impact of adolescent cannabis use, mood disorder and lack of education on attempted suicide in young adulthood. World Psychiatry. 2014;13(3):322–3.

    PubMed  PubMed Central  Google Scholar 

  20. Silins E, Horwood LJ, Patton GC, Fergusson DM, Olsson CA, Hutchinson DM, et al. Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiatry. 2014;1(4):286–93.

    PubMed  Google Scholar 

  21. Arendt M, Munk-Jørgensen P, Sher L, Jensen SO. Mortality following treatment for cannabis use disorders: predictors and causes. J Subst Abus Treat. 2013;44(4):400–6.

    Google Scholar 

  22. Hezel FX. Cultural patterns in Trukese suicide. Ethnology. 1984;23(3):193–206.

    CAS  PubMed  Google Scholar 

  23. Garnefski N, Wilde EJ. Addiction-risk behaviours and suicide attempts in adolescents. J Adolescence. 1998;21(2):135–42.

    CAS  Google Scholar 

  24. Beautrais AL, Joyce PR, Mulder RT. Cannabis abuse and serious suicide attempts. Addiction. 1999;94(8):1155–64.

    CAS  PubMed  Google Scholar 

  25. Gex CR, Narring F, Ferron C, Michaud P. Suicide attempts among adolescents in Switzerland: Prevalence, associated factors and comorbidity. Acta Psychiatr Scand. 1998;98(1):28–33.

    Google Scholar 

  26. Kung HC, Pearson JL, Liu X. Risk factors for male and female suicide decedents ages 15–64 in the United States. Soc Psychiatry Psychiatr Epidemiol. 2003;38(8):419–26.

    PubMed  Google Scholar 

  27. Pedersen W. Does cannabis use lead to depression and suicidal behaviours? A population-based longitudinal study. Acta Psychiatr Scand. 2008;118(5):395–403.

    CAS  PubMed  Google Scholar 

  28. Price C, Hemmingsson T, Lewis G, Zammit S, Allebeck P. Cannabis and suicide: longitudinal study. Br J Psychiatry. 2009;195(6):492–7.

    PubMed  Google Scholar 

  29. Madigan D, Stang PE, Berlin JA, Schuemie M, Overhage JM, Suchard MA, et al. A systematic statistical approach to evaluating evidence from observational studies. Annu Rev Stat Appl. 2014;1:11–39.

    Google Scholar 

  30. Patton GC, Coffey C, Carlin JB, Sawyer SM, Lynskey M. Reverse gateways? Frequent cannabis use as a predictor of tobacco initiation and nicotine dependence. Addiction. 2005;100(10):1518–25.

    PubMed  Google Scholar 

  31. Rasic D, Weerasinghe S, Asbridge M, Langille DB. Longitudinal associations of cannabis and illicit drug use with depression, suicidal ideation and suicidal attempts among Nova Scotia high school students. Drug Alcohol Depend. 2013;129(1–2):49–53.

    PubMed  Google Scholar 

  32. Agrawal A, Nelson EC, Bucholz KK, Tillman R, Grucza RA, Statham DJ, Madden PA, Martin NG, Heath AC, Lynskey MT. Major depressive disorder, suicidal thoughts and behaviours, and cannabis involvement in discordant twins: a retrospective cohort study. Lancet Psychiatry. 2017;4(9):706–14.

    PubMed  PubMed Central  Google Scholar 

  33. Borges G, Bagge CL, Orozco R. A literature review and meta-analyses of cannabis use and suicidality. J Affect Disord. 2016;195:63–74.

    PubMed  Google Scholar 

  34. Chandra S, Radwan MM, Majumdar CG, Church JC, Freeman TP, ElSohly MA. New trends in cannabis potency in USA and Europe during the last decade (2008–2017). Eur Arch Psychiatry Clin Neurosci. 2019;269(1):5–15.

    PubMed  Google Scholar 

  35. Carvalho AF, Stubbs B, Vancampfort D, Kloiber S, Maes M, Firth J, Kurdyak PA, Stein DJ, Rehm J, Koyanagi A. Cannabis use and suicide attempts among 86,254 adolescents aged 12–15 years from 21 low and middle-income countries. Eur Psychiatry. 2019;56:8–13.

    PubMed  Google Scholar 

  36. Sellers CM, Diaz-Valdes Iriarte A, Wyman Battalen A, O'Brien KHM. Alcohol and marijuana use as daily predictors of suicide ideation and attempts among adolescents prior to psychiatric hospitalization. Psychiatry Res. 2019;273:672–7.

    PubMed  Google Scholar 

  37. Conwell Y, Van Orden K, Caine ED. Suicide in older adults. Psychiatr Clin North Am. 2011;34(2):451–68.

    PubMed  PubMed Central  Google Scholar 

  38. Gobbi G, Atkin T, Zytynski T, Wang S, Askari S, Boruff J, et al. Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: a systematic review and meta-analysis. JAMA Psychiat. 2019; https://doi.org/10.1001/jamapsychiatry.2018.4500. [Epub ahead of print]

  39. Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry. 2015;76(9):1174–80.

    PubMed  PubMed Central  Google Scholar 

  40. Allan NP, Ashrafioun L, Kolnogorova K, Raines AM, Hoge CW, Stecker T. Interactive effects of PTSD and substance use on suicidal ideation and behavior in military personnel: increased risk from marijuana use. Depress Anxiety. 2019; https://doi.org/10.1002/da.22954. [Epub ahead of print]

  41. Gentes EL, Schry AR, Hicks TA, Clancy CP, Collie CF, Kirby AC, Dennis MF, Hertzberg MA, Beckham JC, Calhoun PS. Prevalence and correlates of cannabis use in an outpatient VA posttraumatic stress disorder clinic. Psychol Addict Behav. 2016;30(3):415–21.

    PubMed  PubMed Central  Google Scholar 

  42. Kimbrel NA, Meyer EC, DeBeer BB, Gulliver SB, Morissette SB. The impact of cannabis use disorder on suicidal and nonsuicidal self-injury in Iraq/Afghanistan-Era veterans with and without mental health disorders. Suicide Life Threat Behav. 2018;48(2):140–8.

    PubMed  Google Scholar 

  43. Adkisson K, Cunningham KC, Dedert EA, Dennis MF, Calhoun PS, Elbogen EB, Beckham JC, Kimbrel NA. Cannabis use disorder and post-deployment suicide attempts in Iraq/Afghanistan-Era veterans. Arch Suicide Res. 2019;23(4):678–87.

    PubMed  Google Scholar 

  44. Vandrey RG, Budney AJ, Hughes JR, Liguori A. A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances. Drug Alcohol Depend. 2008;92(1–3):48–54.

    CAS  PubMed  Google Scholar 

  45. Degenhardt L, Ferrari AJ, Calabria B, Hall WD, Norman RE, McGrath J, et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. PLoS One. 2013;8(10):e76635.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Agrawal A, Lynskey MT. Cannabis controversies: how genetics can inform the study of comorbidity. Addiction. 2014;109(3):360–70.

    PubMed  PubMed Central  Google Scholar 

  47. Walsh Z, Gonzalez R, Crosby K, Thiessen MS, Carroll C, Bonn-Miller MO. Medical cannabis and mental health: a guided systematic review. Clin Psychol Rev. 2017;51:15–29.

    PubMed  Google Scholar 

  48. Kposowa A, Hamilton D, Wang K. Impact of firearm availability and gun regulation on state suicide rates. Suicide Life Threat Behav. 2016;46(6):678–96.

    PubMed  Google Scholar 

  49. Smith TW, Son J. Trends in gun ownership in the United States, 1972–2014. General Social Survey final report. Chicago: University of Chicago: NORC; 2015.

    Google Scholar 

  50. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry. 2005;62(2):165–72.

    CAS  PubMed  Google Scholar 

  51. Lu CY, Zhang F, Lakoma MD, Madden JM, Rusinak D, Penfold RB, et al. Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study. BMJ. 2014;348:g3596.

    PubMed  PubMed Central  Google Scholar 

  52. Laido Z, Voracek M, Till B, Pietschnig J, Eisenwort B, Dervic K, et al. Epidemiology of suicide among children and adolescents in Austria, 2001–2014. Wien Klin Wochenschr. 2017;129(3–4):121–8.

    PubMed  Google Scholar 

  53. Cohen PN. Recession and divorce in the United States, 2008–2011. Popul Res Policy Rev. 2014;33(5):615–28.

    PubMed  PubMed Central  Google Scholar 

  54. Twenge JM, Campbell WK. Media use is linked to lower psychological well-being: evidence from three datasets. Psychiatry Q. 2019;90:311. [Epub ahead of print].

    Google Scholar 

  55. Brenner B, Cheng D, Clark S, Camargo CA Jr. Positive association between altitude and suicide in 2584 US counties. High Alt Med Biol. 2011;12(1):31–5.

    PubMed  PubMed Central  Google Scholar 

  56. Kim J, Choi N, Lee YJ, An H, Kim N, Yoon HK, Lee HJ. High altitude remains associated with elevated suicide rates after adjusting for socioeconomic status: a study from South Korea. Psychiatry Investig. 2014;11(4):492–4.

    PubMed  PubMed Central  Google Scholar 

  57. Wray M, Miller M, Gurvey J, Carroll J, Kawachi I. Leaving Las Vegas: exposure to Las Vegas and risk of suicide. Soc Sci Med. 2001;67(11):1882–8.

    Google Scholar 

  58. Battersby M, Tolchard B, Scurrah M, Thomas L. Suicide ideation and behaviour in people with pathological gambling attending a treatment service. Int J Ment Health Addict. 2006;4(3):233–46.

    Google Scholar 

  59. Welte JW, Barnes GM, Tidwell MC, Hoffman JH, Wieczorek WF. Gambling and problem gambling in the United States: changes between 1999 and 2013. J Gambl Stud. 2015;31(3):695–715.

    PubMed  PubMed Central  Google Scholar 

  60. Kegler SR, Stone DM, Holland KM. Trends in suicide by level of urbanization – United States, 1999–2015. MMWR Morb Mortal Wkly Rep. 2017;66(10):270–3.

    PubMed  PubMed Central  Google Scholar 

  61. Bounoua L, Nigro J, Zhang P, Thome K, Lachir A. Mapping urbanization in the United States from 2001 to 2011. Appl Geogr. 2018;90:123–33.

    Google Scholar 

  62. Brooks B, McBee M, Pack R, Alamian A. The effects of rurality on substance use disorder diagnosis: a multiple-groups latent class analysis. Addict Behav. 2017;68:24–9.

    PubMed  Google Scholar 

  63. Habecker P, Welch-Lazoritz M, Dombrowski K. Rural and urban differences in Nebraskans’ access to marijuana, methamphetamine, heroin, and prescription pills. J Drug Issues. 2018;48(4):608–24.

    Google Scholar 

  64. Bukky M. Urban and rural adolescent drug use and its relationship with classic criminological theories [dissertation]. Columbus: Ohio State University; 2017.

    Google Scholar 

  65. Barr B, Taylor-Robinson D, Scott-Samuel A, McKee M, Stuckler D. Suicides associated with the 2008–10 economic recession in England: time trend analysis. BMJ. 2012;345:e5142.

    PubMed  PubMed Central  Google Scholar 

  66. Lewis G, Sloggett A. Suicide, deprivation, and unemployment: record linkage study. BMJ. 1998;317(7168):1283–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Kposowa AJ. Unemployment and suicide: a cohort analysis of social factors predicting suicide in the US National Longitudinal Mortality Study. Psychol Med. 2001;31(1):127–38.

    CAS  PubMed  Google Scholar 

  68. Blakely TA, Collings SC, Atkinson J. Unemployment and suicide. Evidence for a causal association? J Epidemiol Community Health. 2003;57(8):594–600.

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Mäki N, Martikainen P. A register-based study on excess suicide mortality among unemployed men and women during different levels of unemployment in Finland. J Epidemiol Community Health. 2012;66(4):302–7.

    PubMed  Google Scholar 

  70. Classen TJ, Dunn RA. The effect of job loss and unemployment duration on suicide risk in the United States: a new look using mass-layoffs and unemployment duration. Health Econ. 2012;21(3):338–50.

    PubMed  Google Scholar 

  71. Azofeifa A, Mattson ME, Schauer G, McAfee T, Grant A, Lyerla R. National estimates of marijuana use and related indicators – National Survey on Drug Use and Health, United States, 2002–2014. In: Morbidity and mortality weekly report. Centers for Disease Control and Preventaion, September 2, 2016.

    Google Scholar 

  72. HIDTA. Rocky mountain high intensity drug trafficking area report, The legalization of marijuana in Colorado: the impact, vol. 4. Denver: Rocky Mountain High Intensity Drug Trafficking Area Investigative Support Center; 2016.

    Google Scholar 

  73. Mohler-Kuo M, Wydler H, Zellweger U, Gutzwiller F. Differences in health status and health behaviour among young Swiss adults between 1993 and 2003. Swiss Med Wkly. 2006;136(29–30):464–72.

    PubMed  Google Scholar 

  74. Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry. 2015;2(3):233–8.

    PubMed  Google Scholar 

  75. Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42(5):1262–9.

    PubMed  PubMed Central  Google Scholar 

  76. Randall JR, Walld R, Finlayson G, Sareen J, Martens PJ, Bolton JM. Acute risk of suicide and suicide attempts associated with recent diagnosis of mental disorders: a population-based, propensity score-matched analysis. Can J Psychiatr. 2014;59(10):531–8.

    Google Scholar 

  77. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005;62(3):247–53.

    PubMed  Google Scholar 

  78. Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol. 2010;24(4 Suppl):81–90.

    PubMed  PubMed Central  Google Scholar 

  79. Mortensen PB, Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry. 1993;163:183–9.

    CAS  PubMed  Google Scholar 

  80. Waterreus A, Di Prinzio P, Badcock JC, Martin-Iverson M, Jablensky A, Morgan VA. Is cannabis a risk factor for suicide attempts in men and women with psychotic illness? Psychopharmacology. 2018;235(8):2275–85.

    CAS  PubMed  Google Scholar 

  81. Cougle JR, Hakes JK, Macatee RJ, Chavarria J, Zvolensky MJ. Quality of life and risk of psychiatric disorders among regular users of alcohol, nicotine, and cannabis: an analysis of the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). J Psychiatric Res. 2015;66–67:135–41.

    Google Scholar 

  82. Chen YW, Dilsaver SC. Lifetime rates of suicide attempts among subjects with bipolar and unipolar disorders relative to subjects with other Axis I disorders. Biol Psychiatry. 1996;39(10):896–9.

    CAS  PubMed  Google Scholar 

  83. Webb RT, Lichtenstein P, Larsson H, Geddes JR, Fazel S. Suicide, hospital-presenting suicide attempts, and criminality in bipolar disorder: examination of risk for multiple adverse outcomes. J Clin Psychiatry. 2014;75(8):e809–16.

    PubMed  PubMed Central  Google Scholar 

  84. Blair-West GW, Cantor CH, Mellsop GW, Eyeson-Annan ML. Lifetime suicide risk in major depression: sex and age determinants. J Affect Disord. 1999;55(2–3):171–8.

    CAS  PubMed  Google Scholar 

  85. Bostwick JM, Pankratz VS. Affective disorders and suicide risk: a reexamination. Am J Psychiatry. 2000;157(12):1925–32.

    CAS  PubMed  Google Scholar 

  86. Sharma T, Guski LS, Freund N, Gøtzsche PC. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ. 2016;352:i65.

    PubMed  PubMed Central  Google Scholar 

  87. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry. 2006;63(12):1358–67.

    CAS  PubMed  Google Scholar 

  88. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA. 2004;292(3):338–43.

    CAS  PubMed  Google Scholar 

  89. Björkenstam C, Möller J, Ringbäck G, Salmi P, Hallqvist J, Ljung R. An association between initiation of selective serotonin reuptake inhibitors and suicide – a nationwide register-based case-crossover study. PLoS One. 2013;8(9):e73973.

    PubMed  PubMed Central  Google Scholar 

  90. Leon AC, Solomon DA, Li C, Fiedorowicz JG, Coryell WH, Endicott J, et al. Antidepressants and risks of suicide and suicide attempts: a 27-year observational study. J Clin Psychiatry. 2011;72(5):580–6.

    PubMed  PubMed Central  Google Scholar 

  91. Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf. 2003;12(5):423–4.

    PubMed  Google Scholar 

  92. Haukka J, Tiihonen J, Härkänen T, Lönnqvist J. Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiol Drug Saf. 2008;17(7):686–96.

    PubMed  Google Scholar 

  93. Kiviniemi M, Suvisaari J, Koivumaa-Honkanen H, Häkkinen U, Isohanni M, Hakko H. Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up. Schizophr Res. 2013;150(1):274–80.

    PubMed  Google Scholar 

  94. Reutfors J, Bahmanyar S, Jönsson EG, Brandt L, Bodén R, Ekbom A, et al. Medication and suicide risk in schizophrenia: a nested case-control study. Schizophr Res. 2013;150(2–3):416–20.

    PubMed  Google Scholar 

  95. Kasckow J, Felmet K, Zisook S. Managing suicide risk in patients with schizophrenia. CNS Drugs. 2011;25(2):129–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  96. Khan A, Khan SR, Leventhal RM, Brown WA. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database. Am J Psychiatry. 2001;158(9):1449–54.

    CAS  PubMed  Google Scholar 

  97. Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand. 2001;104(3):163–72.

    CAS  PubMed  Google Scholar 

  98. Yerevanian BI, Koek RJ, Mintz J. Lithium, anticonvulsants and suicidal behavior in bipolar disorder. J Affect Disord. 2003;73(3):223–8.

    CAS  PubMed  Google Scholar 

  99. Toffol E, Hätönen T, Tanskanen A, Lönnqvist J, Wahlbeck K, Joffe G, et al. Lithium is associated with decrease in all-cause and suicide mortality in high-risk bipolar patients: a nationwide registry-based prospective cohort study. J Affect Disord. 2015;183:159–65.

    CAS  PubMed  Google Scholar 

  100. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. 2007;64(3):327–37.

    CAS  PubMed  Google Scholar 

  101. Ikemoto S, Panksepp J. The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Brain Res Brain Res Rev. 1999;31(1):6–41.

    CAS  PubMed  Google Scholar 

  102. Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science. 1997;278(5335):52–8.

    CAS  PubMed  Google Scholar 

  103. Francis TC, Gantz SC, Moussawi K, Bonci A. Synaptic and intrinsic plasticity in the ventral tegmental area after chronic cocaine. Curr Opin Neurobiol. 2019;54:66–72.

    CAS  PubMed  Google Scholar 

  104. Lecca D, Cacciapaglia F, Valentini V, Di Chiara G. Monitoring extracellular dopamine in the rat nucleus accumbens shell and core during acquisition and maintenance of intravenous WIN 55,212-2 self-administration. Psychopharmacology. 2006;188(1):63–74.

    CAS  PubMed  Google Scholar 

  105. Fadda P, Scherma M, Spano MS, Salis P, Melis V, Fattore L, et al. Cannabinoid self-administration increases dopamine release in the nucleus accumbens. Neuroreport. 2006;17(15):1629–32.

    CAS  PubMed  Google Scholar 

  106. Bossong MG, Mehta MA, van Berckel BN, Howes OD, Kahn RS, Stokes PR. Further human evidence for striatal dopamine release induced by administration of ∆9-tetrahydrocannabinol (THC): selectivity to limbic striatum. Psychopharmacology. 2015;232(15):2723–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  107. Silveira MM, Arnold JC, Laviolette SR, Hillard CJ, Celorrio M, Aymerich MS, et al. Seeing through the smoke: human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks. Neurosci Biobehav Rev. 2017;76(Pt B):380–95.

    CAS  PubMed  Google Scholar 

  108. Uhl GR, Koob GF, Cable J. The neurobiology of addiction. Ann N Y Acad Sci. 2019; 1451(1): 5–28.

    Google Scholar 

  109. Bloomfield MA, Ashok AH, Volkow ND, Howes OD. The effects of Δ9-tetrahydrocannabinol on the dopamine system. Nature. 2016;539(7629):369–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  110. Martin-Soelch C. Is depression associated with dysfunction of the central reward system? Biochem Soc Trans. 2009;37(Pt 1):313–7.

    CAS  PubMed  Google Scholar 

  111. Schneier FR, Slifstein M, Whitton AE, Pizzagalli DA, Reinen J, McGrath PJ, et al. Dopamine release in antidepressant-naive major depressive disorder: a multimodal [11C]-(+)-PHNO positron emission tomography and functional magnetic resonance imaging study. Biol Psychiatry. 2018;84(8):563–73.

    CAS  PubMed  PubMed Central  Google Scholar 

  112. Zimmermann K. Reward and affective dysregulation in cannabis users. Doctoral dissertation, University of Dusseldorf, 2018. 66 pp.

    Google Scholar 

  113. Blum K, Cull JG, Braverman ER, Comings DE. Reward deficiency syndrome. Am Scientist. 1996;84:132–45.

    Google Scholar 

  114. Russo M, Rifici C, Sessa E, D’Aleo G, Bramanti P, Calabrò RS. Sativex-induced neurobehavioral effects: causal or concausal? A practical advice! Daru. 2015;23(1):25.

    PubMed  PubMed Central  Google Scholar 

  115. Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(17):1556–63.

    PubMed  PubMed Central  Google Scholar 

  116. Gorelick DA, Goodwin RS, Schwilke E, Schwope DM, Darwin WD, Kelly DL, et al. Antagonist-elicited cannabis withdrawal in humans. J Clin Psychopharmacol. 2011;31(5):603–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  117. Robertson HT, Allison DB. Drugs associated with more suicidal ideations are also associated with more suicide attempts. PLoS One. 2009;4(10):e7312.

    PubMed  PubMed Central  Google Scholar 

  118. Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol. 2008;20(S1):10–4.

    CAS  PubMed  Google Scholar 

  119. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770–804.

    CAS  PubMed  PubMed Central  Google Scholar 

  120. Lemberger L, Martz R, Rodda B, Forney R, Rowe H. Comparative pharmacology of Delta9-tetrahydrocannabinol and its metabolite, 11-OH-Delta9-tetrahydrocannabinol. J Clin Invest. 1973;52(10):2411–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  121. Favrat B, Ménétrey A, Augsburger M, Rothuizen LE, Appenzeller M, Buclin T, et al. Two cases of “cannabis acute psychosis” following the administration of oral cannabis. BMC Psychiatry. 2005;5:17.

    PubMed  PubMed Central  Google Scholar 

  122. Sublette ME, Galfalvy HC, Fuchs D, Lapidus M, Grunebaum MF, Oquendo MA, et al. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav Immun. 2011;25(6):1272–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  123. Bradley KA, Case JA, Khan O, Ricart T, Hanna A, Alonso CM, et al. The role of the kynurenine pathway in suicidality in adolescent major depressive disorder. Psychiatry Res. 2015;227(2):206–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  124. Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Samuelsson M, et al. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology. 2013;38(5):743–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  125. Brundin L, Sellgren CM, Lim CK, Grit J, Pålsson E, Landen M, et al. An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation. Transl Psychiatry. 2016;6(8):e865.

    CAS  PubMed  PubMed Central  Google Scholar 

  126. Messaoud A, Mensi R, Douki W, Neffati F, Najjar MF, Gobbi G, et al. Reduced peripheral availability of tryptophan and increased activation of the kynurenine pathway and cortisol correlate with major depression and suicide. World J Biol Psychiatry. 2018;23:1–9. https://doi.org/10.1080/15622975.2018.1468031. [Epub ahead of print].

    Article  Google Scholar 

  127. Miller CL, Llenos IC, Cwik M, Walkup J, Weis S. Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. Neurochem Int. 2008;52(6):1297–303.

    CAS  PubMed  Google Scholar 

  128. O'Donovan A, Rush G, Hoatam G, Hughes BM, McCrohan A, Kelleher C, et al. Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety. 2013;30(4):307–14.

    CAS  PubMed  Google Scholar 

  129. Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry. 2009;66(3):287–92.

    CAS  PubMed  Google Scholar 

  130. Janelidze S, Mattei D, Westrin Å, Träskman-Bendz L, Brundin L. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun. 2011;25(2):335–9.

    CAS  PubMed  Google Scholar 

  131. Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood. 2005;106(7):2375–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  132. Massi P, Fuzio D, Viganò D, Sacerdote P, Parolaro D. Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity. Eur J Pharmacol. 2000;387(3):343–7.

    CAS  PubMed  Google Scholar 

  133. McKallip RJ, Lombard C, Martin BR, Nagarkatti M, Nagarkatti PS. Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Ther. 2002;302(2):451–65.

    CAS  PubMed  Google Scholar 

  134. Li X, Kaminski NE, Fischer LJ. Examination of the immunosuppressive effect of delta9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes. Int Immunopharmacol. 2001;1(4):699–712.

    CAS  PubMed  Google Scholar 

  135. Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Vogel Z. Cannabinoids delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem. 2010;285(3):1616–26.

    CAS  PubMed  Google Scholar 

  136. Poddar MK, Ghosh JJ. Effect of cannabis extract, Δ9-tetrahydrocannabinol and lysergic acid diethylamide on rat liver enzymes. Biochem Pharmacol. 1972;21(24):3301–3.

    CAS  PubMed  Google Scholar 

  137. Doshi A, Boudreaux ED, Wang N, Pelletier AJ, Camargo CA. National study of US emergency department visits for attempted suicide and self-inflicted injury, 1997–2001. Ann Emerg Med. 2005;46(4):369–75.

    PubMed  Google Scholar 

Cannabis Use Disorder, Treatment, and Recovery

  1. Budney AJ, Roffman R, Stephens RS, Walker D. Marijuana dependence and its treatment. Addict Sci Clin Pract. 2007;4(1):4–16.

    PubMed  PubMed Central  Google Scholar 

  2. Prochaska JO, DiClemente CC, Norcross JC. In search of how people change: applications to the addictive behaviors. Am Psychologist. 1992;47:1102–14.

    CAS  Google Scholar 

  3. Prochaska JO, Redding CA, Evers K. The transtheoretical model and atages of change. In: Glanz K, Rimer BK, Lewis FM, editors. Health and behaviors and health education theory, research and practice. 3rd ed. San Francisco: Jossey-Bass, Inc.; 2002.

    Google Scholar 

  4. American Society of Addiction Medicine. Criteria: treatment criteria for addictive, substance-related, and co-occurring conditions. 3rd edn. Carson City, NV: The Change Companies. 2013.

    Google Scholar 

  5. Pacheco-Colón I, Limia JM, Gonzalez R. Nonacute effects of cannabis use on motivation and reward sensitivity in humans: a systematic review. Psychol Addict Behav. 2018;32(5):497–507.

    PubMed  PubMed Central  Google Scholar 

  6. Marijuana Anonymous World Service. 2019. http://www.marijuana-anonymous.org.

  7. Marijusana Anonymous. Life with hope 12 step workbook: a return to living through the 12 steps and 12 traditions of marijuana anonymous.

    Google Scholar 

  8. Venice N, Tung G. Marijuana and child abuse and neglect: a health impact assessment. Aurora: Colorado School of Public Health; 2016.

    Google Scholar 

  9. Few L, et al. Cannabis involvement and nonsuicidal self-injury: a discordant twin approach. J Stud Alcohol Drugs. 2016;77(6):873–80.

    PubMed  PubMed Central  Google Scholar 

  10. Rossow I, Hawton K, Ystgaard M. Cannabis use and deliberate self-harm in adolescence: a comparative analysis of associations in England and Norway. Arch Suicide Res. 2009;13(4):340–8.

    PubMed  Google Scholar 

  11. Yassa AH, George SM. Cannabis abuse and self-mutilation. J Forensic Sci Criminol. 2016;4(5). ISSN: 2348–9804.

    Google Scholar 

  12. Delteil C, et al. Death by self-mutilation after oral cannabis consumption. Legal Med Tokyo. 2018;30:5–9.

    Google Scholar 

  13. Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6:427–36.

    PubMed  Google Scholar 

  14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: diagnostic and statistical manual of mental disorders, 5th edn. Arlington, VA: American Psychiatric Association, 2013.

    Google Scholar 

  15. World Health Organization. International statistical classification of diseases and related health problems, tenth revision. 5th edn. 2015, 2016. Geneva: World Health Organization.

    Google Scholar 

  16. Hall W. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? s. 2015;110(1):19–35.

    Google Scholar 

  17. Sherman BJ, McRae-Clark AL. Treatment of cannabis use disorder: current science and future outlook. Pharmacotherapy. 2016;36(5):511–35.

    PubMed  PubMed Central  Google Scholar 

  18. Stephens RS, Roffman RA, Simpson EE. Treating adult marijuana dependence: a test of the relapse prevention model. J Consult Clin Psychol. 1994;1:92–9. [PubMed: 8034835].

    Google Scholar 

  19. Hoch E, Bühringer G, Pixa A, Dittmer K, Henker J, Seifert A, Wittchen HU. CANDIS treatment program for cannabis use disorders: findings from a randomized multi-site translational trial. Drug Alcohol Depend. 2014;134:185–93.

    CAS  PubMed  Google Scholar 

  20. Stephens RS, Roffman RA, Fearer SA, Williams C, Burke RS. The marijuana check-up: promoting change in ambivalent marijuana users. Addiction. 2007;6:947–57. [PubMed: 17523990].

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Child, Adolescent, and Family Unit, Vermont Department of Mental Health, Psychiatry and Pediatrics, University of Vermont Larner College of Medicine, @Pedipsych, Burlington, VT, USA

    David C. Rettew

  2. Department of Psychiatry, University of Colorado, Colorado Physician Health Program, Boulder, CU, USA

    Doris C. Gundersen

  3. Department of Psychiatry, University of Colorado School of Medicine, Aurora, CO, USA

    Erica Kirsten Rapp & Paula Riggs

  4. MillerBio, Baltimore, MD, USA

    Christine L. Miller

  5. Department of Mathematics and Statistics, American University, Washington, DC, USA

    Monica C. Jackson

  6. Department of Psychiatry, Yale University, New Haven, CT, USA

    Kevin Sabet

  7. Cort Consulting, Longmont, CO, USA

    Ben Cort

  8. Women’s Recovery, Denver, CO, USA

    LaTisha L. Bader

Authors
  1. David C. Rettew
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Doris C. Gundersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erica Kirsten Rapp
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paula Riggs
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christine L. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Monica C. Jackson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kevin Sabet
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ben Cort
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. LaTisha L. Bader
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David C. Rettew .

Editor information

Editors and Affiliations

  1. Springs Rehabilitation PC, Colorado Springs, CO, USA

    Kenneth Finn

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rettew, D.C. et al. (2020). Cannabis and Neuropsychiatric Effects. In: Finn, K. (eds) Cannabis in Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-45968-0_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-45968-0_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-45967-3

  • Online ISBN: 978-3-030-45968-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation